News

Serum neurofilament light: A biomarker for disease activity in MS

1920 1080 Mea Holm, PhD

How close are we to establishing a reliable liquid biomarker for detecting disease onset, progression and treatment response in multiple sclerosis? According to Dr Peter Calabresi (Johns Hopkins, USA) at…

read more

Results from the MS-SMART trial unveiled

3971 2975 Mea Holm, PhD

Secondary progressive multiple sclerosis (SPMS) is known to be extremely difficult to treat; there are no effective therapies for halting or reversing disability progression in the late disease phase. In…

read more

De-risking PML: A conversation with Prof. Walter Atwood

2872 2598 Prof. Dr. Krassen Nedeltchev

We interviewed Professor Walter Atwood last week at the 2018 ECTRIMS congress in Berlin, Germany, to learn about advances in treating progressive multifocal leukoencephalopathy (PML) – an important treatment-associated infection…

read more

Fighting neurodegeneration in MS

3150 2100 Mea Holm, PhD

The pathology of multiple sclerosis (MS) involves not only the loss of myelin sheets around the axons of neurons, but also the fragmentation of the axons themselves. At ECTRIMS 2018,…

read more

MS treatment strategy: Hitting hard and early, or minimising risks through stepwise escalation?

1969 1525 Mea Holm, PhD

With more than a dozen approved treatment options for relapsing-remitting multiple sclerosis (RRMS), treatment decision making is an increasingly complex task for neurologists. At ECTRIMS 2018, the topic on which…

read more

FLOODLIGHT offers illuminating outcomes for smartphone monitoring in MS

1920 1080 Peter Stevenson, PhD

Smartphone-based, high-yield active and passive self-monitoring of multiple sclerosis (MS) may enhance clinical disease assessments when compared to conventional methods for detecting subtle progressive clinical changes, according to a study…

read more

New molecule could halt neural damage in Parkinson’s disease

2967 1980 Peter Stevenson, PhD

Researchers may have found a way to halt, and even reverse, the neural damage associated with Parkinson’s disease (PD) using a novel molecule that targets a key cause of nerve…

read more

Restoring “conductor” cells in the orchestra of schizophrenia

2850 1900 Peter Stevenson, PhD

Key symptoms of schizophrenia, including hallucinations, hyperactivity and impaired memory, could be caused by desynchronised cells in the brain, recent research published in Nature Neuroscience has revealed. The authors investigated…

read more

3 minutes with Prof. Goadsby – Interview from SNG

150 150 Rachel Park, MA

Professor Peter Sandor interviewed Professor Peter Goadsby at the SNG Annual Meeting this week in Montreux, Switzerland. They spoke about one of the top leading causes of disability–migraine. Watch the…

read more

Paralysis patients able to walk after epidural stimulation

3016 1900 Peter Stevenson, PhD

Patients with complete lower limb paralysis after spinal cord injury (SCI) have been given the ability to walk again, it was reported this week. In work published in Nature Medicine,…

read more
Brainwork is supported by unrestricted grants from: